Tommaso Martino De Pas
Humanitas Gavazzeni · 70 works · 2,226 citations · h-index 21
Top works
- Results of a global phase II study with crizotinib in advanced ALK-positive non-small cell lung cancer (NSCLC).
- An Individual Patient Data Metaanalysis of Outcomes and Prognostic Factors After Treatment of Oligometastatic Non–Small-Cell Lung Cancer
- Initial phase II results with crizotinib in advanced ALK-positive non-small cell lung cancer (NSCLC): PROFILE 1005.
- Early Prediction of Response to Tyrosine Kinase Inhibitors by Quantification of EGFR Mutations in Plasma of NSCLC Patients
- Grading the neuroendocrine tumors of the lung: an evidence-based proposal
- First-in-human phase I study of the ALK inhibitor LDK378 in advanced solid tumors.
- Large-Cell Neuroendocrine Carcinoma of the Lung Harboring EGFR Mutation and Responding to Gefitinib
- The Activity of Chemotherapy in Inflammatory Myofibroblastic Tumors: A Multicenter, European Retrospective Case Series Analysis
- Pharmacogenetics of Anticancer Drug Sensitivity in Non-Small Cell Lung Cancer
- Stem Cell Transplantation Effectively Occludes Bronchopleural Fistula in an Animal Model
- Phase II Study of Asparagine-Glycine-Arginine–Human Tumor Necrosis Factor α, a Selective Vascular Targeting Agent, in Previously Treated Patients With Malignant Pleural Mesothelioma
- Oligometastatic Non–Small Cell Lung Cancer: A Multidisciplinary Approach in the Positron Emission Tomographic Scan Era
- The sacral chordoma margin
- Phase I Study of NGR-hTNF, a Selective Vascular Targeting Agent, in Combination with Cisplatin in Refractory Solid Tumors
- EGFR tyrosine kinase inhibitors beyond focal progression obtain a prolonged disease control in patients with advanced adenocarcinoma of the lung
- Safety and Immunogenicity of MAGE-A3 Cancer Immunotherapeutic with or without Adjuvant Chemotherapy in Patients with Resected Stage IB to III MAGE-A3-Positive Non-Small-Cell Lung Cancer
- Avelumab plus axitinib in unresectable or metastatic type B3 thymomas and thymic carcinomas (CAVEATT): a single-arm, multicentre, phase 2 trial
- Guideline-Based Follow-Up Outcomes in Patients With Gastrointestinal Stromal Tumor With Low Risk of Recurrence
- Visual effects in anaplastic lymphoma kinase ( ALK )-positive advanced non-small cell lung cancer (NSCLC) patients treated with crizotinib.
- Targeting ALK in patients with advanced Non Small Cell Lung Cancer: Biology, diagnostic and therapeutic options